Two Cases of Primary Malignant Melanoma Treated by Selective Melanoma Thermal Neutron Capture Therapy
In 1972, the study of Selective Melanoma Thermal Neutron Capture Therapy (Selective-Melanoma NCT) was initiated by Mishima’s group1). In order to apply the theory that reaction products between 10B and neutrons can destroy cells containing 10B 2), 10B had to be transported into malignant melanoma (Mm) cells. For that purpose, 10B1-para-borono-phenylalanine (10B1-BPA) was synthesized. It is a precursor dopa analogue and accumulates in melanosomes within Mm cells (Fig 1) 3,4). 10B1-BPA was complexed with fructose so that it could be soluble at pH near 7.4 (almost equal to blood pH) and be suitable for Selective-Melanoma NCT 5). The first clinical application to metastatic Mm was performed successfully in 1987 1, 6–8). Since then 16 cases of Mm have been treated. Here we report a case of lentigo maligna melanoma on the right face and a case of acral lentiginous melanoma on the right sole, treated by Selective-Melanoma NCT.
KeywordsInductively Couple Plasma Atomic Emission Spectrometry Thermal Neutron Primary Malignant Melanoma Boron Neutron Capture Therapy Lithium Atom
Unable to display preview. Download preview PDF.
- 9.T. Kobayashi, K. Kanda, Y. Ujeno, H. Fukuda, K. Ando, J. Hiratsuka, Y. Mishima, and M. Ichihashi, Irradiation conditions based on absorbed dose estimation in boron neutron capture therapy for superficially located malignant melanoma, Radiat Biol Res Commun, 25: 53–64. 1990.Google Scholar
- 11.K. Yoshino, C. Nishino, E. Ubukata, T. Maruyama, Y. Mori, Y. Mishima, C. Honda, M. Shiono, N. Wadabayashi, M. Ichihashi, T. Kobayashi, and K. Kanda, Rapid spectrophotometric determination of boron in biological tissue with alkali fusion decomposition, in “Progress in Neutron Capture for Cancer”, Plenum Press, New York, 1992, pp. 309–312.CrossRefGoogle Scholar
- 12.H. Fukuda, J. Hiratsuka, C. Honda, T. Kobayashi, K. Yoshino, H. Karashima, J. Takahashi, Y. Abe, K. Kanda, M. Ichihashi, and Y. Mishima, Boron neutron capture therapy of malignant melanoma using 1°B1-para-boronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin, Radiat Res, 138: 435–442, 1994.PubMedCrossRefGoogle Scholar